Prevents osteoporosis in postmenopausal women ( 1.1, 1.2 ). ANDA 76768, held by Cipla. Alendronate Sodium.
As of Nov 16, 2026, ANDA 76768 (Alendronate Sodium), held by Cipla, was first approved by FDA on Aug 4, 2008, with 4 approved supplements and 0 published complete response letters.
Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1, 1.2 ) Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget's disease of bone Limitations of use: Optimal duration of use has not been determined. For patients at low- risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 40MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Jan 15, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 12, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 12, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 7, 2011 | Supplement 2Labeling | Approved | None posted |
| Aug 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters